A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ genetics
Bleomycin
/ administration & dosage
Cohort Studies
Dacarbazine
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Fluorodeoxyglucose F18
/ metabolism
Hodgkin Disease
/ diagnostic imaging
Humans
Male
Middle Aged
Positron-Emission Tomography
/ methods
Prognosis
ROC Curve
Radiopharmaceuticals
/ metabolism
Transcriptome
Vinblastine
/ administration & dosage
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 01 2020
15 01 2020
Historique:
received:
20
07
2019
revised:
12
09
2019
accepted:
15
10
2019
pubmed:
28
10
2019
medline:
2
10
2020
entrez:
25
10
2019
Statut:
ppublish
Résumé
Early response to ABVD, assessed with interim FDG-PET (iPET), is prognostic for classical Hodgkin lymphoma (cHL) and supports the use of response adapted therapy. The aim of this study was to identify a gene-expression profile on diagnostic biopsy to predict iPET positivity (iPET Consecutive untreated patients with stage I-IV cHL who underwent iPET after two cycles of ABVD were identified. Expression of 770 immune-related genes was analyzed by digital expression profiling (NanoString Technology). iPET was centrally reviewed according to the five-point Deauville scale (DS 1-5). An iPET A training set of 121 and a validation set of 117 patients were identified, with 23 iPET In cHL, iPET is associated with a genetic signature and can be predicted by applying an integrated gene-based model on the diagnostic biopsy.
Identifiants
pubmed: 31645353
pii: 1078-0432.CCR-19-2356
doi: 10.1158/1078-0432.CCR-19-2356
doi:
Substances chimiques
Biomarkers, Tumor
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Bleomycin
11056-06-7
Vinblastine
5V9KLZ54CY
Dacarbazine
7GR28W0FJI
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
373-383Informations de copyright
©2019 American Association for Cancer Research.